A drug commonly used to treat osteoporosis could benefit women undergoing treatment for breast cancer, research presented at the San Antonio Breast Cancer Symposium has shown.
Patients taking the breast cancer drug anastrozole often experience loss of bone mineral density, placing them at risk of osteoporosis and fractures.
A trial involving the osteoporosis drug bisphosphonate has now revealed that breast cancer patients taking the drug had increased bone mineral density after one year, despite having low density at the start of the trial.
The results are only preliminary, but the researchers hope that the three-year data from the IBIS-2 trial will confirm the drug's effectiveness.
Professor Jack Cuzick, co-chairman of the trial, said: 'Although these are still very early results, they are reassuring for women participating in the IBIS-2 trial and also for those who may be taking anastrozole as part of their treatment for breast cancer.'
Patients taking the breast cancer drug anastrozole often experience loss of bone mineral density, placing them at risk of osteoporosis and fractures.
A trial involving the osteoporosis drug bisphosphonate has now revealed that breast cancer patients taking the drug had increased bone mineral density after one year, despite having low density at the start of the trial.
The results are only preliminary, but the researchers hope that the three-year data from the IBIS-2 trial will confirm the drug's effectiveness.
Professor Jack Cuzick, co-chairman of the trial, said: 'Although these are still very early results, they are reassuring for women participating in the IBIS-2 trial and also for those who may be taking anastrozole as part of their treatment for breast cancer.'
Labels: aches and pains
0 comments:
Subscribe to:
Post Comments (Atom)